Ofev (nintedanib) — Medica
Interstitial lung diseases, chronic fibrosing with a progressive phenotype
Initial criteria
- age ≥ 18 years
- Forced vital capacity (FVC) ≥ 40% of predicted value
- Fibrosing lung disease impacts more than 10% of lung volume on high-resolution computed tomography (per prescriber)
- Patient has clinical signs of progression (examples: FVC decline ≥ 10% predicted, or FVC decline ≥ 5% to <10% with worsening symptoms and/or worsening imaging)
- Medication is prescribed by or in consultation with a pulmonologist
Approval duration
1 year